Introducing iNCOVACC®, World’s First Intranasal Vaccine for COVID

iNCOVACC BHARAT BIOTECH

WORLD'S FIRST INTRANASAL VACCINE iNCOVACC

iNCOVACC® is the world’s first Intranasal vaccine for COVID to receive approval for the primary 2-dose schedule and heterologous booster dose.

[{"selector":"#anim-ac472236-ee33-4e69-9f60-c0ef30fe1c25","keyframes":{"opacity":[0,1]},"delay":0,"duration":1200,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-1bdd8b26-3c6c-4b4f-ae40-517411000f24","keyframes":{"transform":["translate3d(100.00000%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":1200,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}]

This vaccine has received emergency use authorization from the Central Drugs Standard Control Organisation (CDSCO).

[{"selector":"#anim-d6fef4f7-c751-4c48-876f-e4c85c30cf4f [data-leaf-element=\"true\"]","keyframes":{"transform":["translate3d(12.514648210040342%, 0, 0)","translate3d(0%, 0, 0)"]},"delay":0,"duration":1200,"easing":"cubic-bezier(.3,0,.55,1)","fill":"both"}]

The nasal route has excellent potential for vaccination due to the organized immune systems of the nasal mucosa.

[{"selector":"#anim-20fcc884-f46c-41e0-8f63-bf22bbd33334 [data-leaf-element=\"true\"]","keyframes":{"transform":["translate(0%, 0%) scale(1.5)","translate(0%, 0%) scale(1)"]},"delay":0,"duration":1200,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}]

iNcovacc is a recombinant replication–deficient adenovirus vectored vaccine with a pre-fusion stabilized spike protein.

[{"selector":"#anim-7520510d-b3b8-44e7-b3c8-0d384e096442 [data-leaf-element=\"true\"]","keyframes":{"transform":["translate3d(0, 6.067961238287115e-7%, 0)","translate3d(0, 0%, 0)"]},"delay":0,"duration":1200,"easing":"cubic-bezier(.3,0,.55,1)","fill":"both"}]

iNcovacc is a needle-free Intranasal vaccine for SARS-CoV-2

[{"selector":"#anim-31c25eef-bcc8-4c5e-8c1e-b2372060eb91 [data-leaf-element=\"true\"]","keyframes":{"transform":["translate(0%, 0%) scale(1)","translate(0%, 0%) scale(1)"]},"delay":0,"duration":1200,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}]

EASY APPLICATION

A user-friendly application that requires no trained health care professionals.

NO NEEDLE INJURIES

CHILDREN & ADULTS

iNcovacc can be manufactured on a large scale to meet global demand.

[{"selector":"#anim-e766cd44-cdbd-4ce2-aa02-ddd6c60a2199 [data-leaf-element=\"true\"]","keyframes":{"transform":["translate(0%, 0%) scale(1)","translate(0%, 0%) scale(1)"]},"delay":0,"duration":1200,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}]

The vaccine is developed by Bharat Biotech in India and has been approved for use in those aged 18 and above.

The Government of India partly funded product development and clinical trials through the Department of Biotechnology’s COVID Suraksha Program.

About Bharat Biotech International : A Recent Achievement in India’s ROTAVIRUS VACCINE – ROTAVAC Enhanced by Bharat Biotech International Limited, add one more crown to the global leader in the Vaccine field. The company has over 145 global patents and produced around 19 vaccines, four therapeutics, and registrations in 1255 countries.

[{"selector":"#anim-c1c9184d-7465-4452-8167-52003960cce0 [data-leaf-element=\"true\"]","keyframes":{"transform":["translate(0%, 0%) scale(1.5)","translate(0%, 0%) scale(1)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}] More Stories